Last reviewed · How we verify
NCT04601701
Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
NA trial testing Bevacizumab Ophthalmic and Intravitreal Dexamethasone. in Central Retinal Vein Occlusion in 100 participants. Status unknown.
30 March 2021
Quick facts
| Lead sponsor | He Eye Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 17 October 2020 |
| Primary completion | 30 March 2021 |
| Estimated completion | 17 September 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Bevacizumab Ophthalmic and Intravitreal Dexamethasone.
- Bevacizumab Ophthalmic.
Conditions studied
- Central Retinal Vein Occlusion — all drugs for Central Retinal Vein Occlusion →
Sponsor
He Eye Hospital
Who can join
18 and older, any sex, with Central Retinal Vein Occlusion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether Bevacizumab (Avastin) in combination with Dexamethasone (Ozurdex) will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO) in comparison to Bevacizumab (Avastin) alone.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04601701
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Central Retinal Vein Occlusion
Currently open trials in the same condition.
- NCT05476926 — A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products · active not recruiting
Other He Eye Hospital trials
Trials by the same sponsor.
- NCT07097922 — Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients With Dry Eye After LASIK · NA · not yet recruiting
- NCT06852105 — Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients with Dry Eye After Trans-PRK · NA · not yet recruiting
- NCT06714994 — Effect of Spectacle Distribution to Myopic Secondary School Students in Rural Communities of Liaoning Province on Commun · NA · not yet recruiting
- NCT06656403 — Effect of Artificial Tears on Ocular Biometry Parameters · NA · not yet recruiting
- NCT06537349 — Effects of 3% Diquafosol on Tear Film and Vision-related Quality of Life in Orthokeratology Lens Related Dry Eye · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04601701 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by He Eye Hospital
- Last refreshed: 26 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04601701.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing